Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
291 stopped studies mapped to Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and descendants · 82% state a reason
Over the 291 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic… | Phase 1 | withdrawn | Nov 23, 2015 | Michael Choi | No participants enrolled | Enrollment / accrual |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT00290407 | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic… | Phase 2 | terminated | Feb 13, 2006 | University of Louisville | terminated due to lack of accrual | Enrollment / accrual |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic… | Phase 2 | terminated | Sep 25, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual, PI left NIH and primary endpoint not met. | Investigator |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | Phase 2 | terminated | Jun 6, 2012 | French Innovative Leukemia Organisation | Other drugs others studies | Other (stated, no rule matched) |
| NCT02020109 | Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia | — | withdrawn | Dec 24, 2013 | Maastricht Radiation Oncology | Logistics and financial | Funding |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants… | Phase 4 | terminated | Jan 6, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT01069432 | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic… | — | withdrawn | Feb 17, 2010 | Dartmouth-Hitchcock Medical Center | IRB delayed their review for an extensive period of time. Funding for this protocol is no longer… | Funding |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or…(VAY736Y) | Phase 1 | terminated | May 14, 2014 | Novartis Pharmaceuticals | Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early… | Safety / toxicity |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | Study Not Activated Due to Contract Issues | Other (stated, no rule matched) |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia… | Phase 2 | terminated | Oct 5, 2011 | European Institute of Oncology | low rate in patient accrual | Enrollment / accrual |
| NCT02200848 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 | terminated | Jul 25, 2014 | Georgetown University | Recruitment difficulties and toxicity | Safety / toxicity |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic… | Phase 2 | withdrawn | Jan 25, 2016 | Fred Hutchinson Cancer Center | Low enrollment | Enrollment / accrual |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 / Phase 2 | withdrawn | Feb 9, 2016 | University of Michigan Rogel Cancer Center | FDA has placed all trials involving Pacritinib on Full Clinical Hold | Other (stated, no rule matched) |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the… | Phase 2 / Phase 3 | terminated | Jul 14, 2008 | University of Alabama at Birmingham | Accrual goals could not be met within a timely manner | Enrollment / accrual |
| NCT00587457 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic… | Phase 1 | terminated | Jan 7, 2008 | MedImmune LLC | The study is terminated early due to unavailability of investigational product. | Other (stated, no rule matched) |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jul 4, 2007 | Genentech, Inc. | not stated | Not stated |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory…(S-BR) | Phase 2 | withdrawn | Dec 8, 2015 | University of Arizona | Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study… | Enrollment / accrual |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell… | Phase 1 | terminated | Jun 4, 2012 | Tufts Medical Center | Unavailability of study article | Other (stated, no rule matched) |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | withdrawn | Other (stated, no rule matched) |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | Phase 2 | terminated | Aug 2, 2010 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application…(CLLIFVAC) | Phase 2 | terminated | Jan 17, 2008 | The Royal Bournemouth Hospital | Recruitment issues | Enrollment / accrual |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte… | Phase 2 | terminated | Aug 7, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT01600053 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | Phase 2 | terminated | May 16, 2012 | Thomas Kipps | interim analysis showed that the trial will not meet the interim endpoint. | Efficacy / futility |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | CTEP Initiated Action. | Other (stated, no rule matched) |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic… | Phase 3 | terminated | Dec 28, 2006 | German CLL Study Group | low recruitment | Enrollment / accrual |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | Phase 2 | terminated | Oct 10, 2008 | Northwell Health | study suspended while data is reviewed for safety and efficacy. | Safety / toxicity |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell… | N/A | terminated | Jul 25, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR) | — | terminated | Oct 24, 2014 | Astellas Pharma International B.V. | The study was terminated due to insufficient subject enrollment and very slow enrollment. | Enrollment / accrual |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 25, 2019source: clinicaltrials